KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has received orphan drug designation by the U.S. Food and Drug Administration (“FDA”) for Rose Bengal, the active ingredient in its novel oncology drug PV-10, for the treatment of hepatocellular carcinoma (“HCC”), the most common form of primary liver cancer. Provectus completed patient accrual and treatment of all subjects in its Phase 1 clinical trial of PV-10 for liver cancer in January 2011, and is currently designing a Phase 2 study.
